CDK2 and breast cancer: Moreover, Kim et al. reported that breast cancer patients with specific high activity of CDK1 and CDK2 had significantly poorer 5 years of relapse-free survival compared to those with low CDK1 and CDK2 activity (Kim et al., 2008), similar to our current observation (Figure 7).